DAFNA Capital Management LLC Purchases 142,500 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

DAFNA Capital Management LLC increased its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 56.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 393,083 shares of the company's stock after purchasing an additional 142,500 shares during the period. DAFNA Capital Management LLC owned 1.19% of Lexeo Therapeutics worth $2,586,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its stake in shares of Lexeo Therapeutics by 5.6% during the 4th quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock worth $333,000 after acquiring an additional 2,677 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Lexeo Therapeutics by 30.1% in the fourth quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after acquiring an additional 3,093 shares in the last quarter. Wells Fargo & Company MN raised its stake in Lexeo Therapeutics by 49.9% in the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock worth $73,000 after purchasing an additional 3,714 shares in the last quarter. Rhumbline Advisers boosted its holdings in Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after purchasing an additional 4,127 shares during the period. Finally, Barclays PLC increased its holdings in shares of Lexeo Therapeutics by 9.9% during the fourth quarter. Barclays PLC now owns 55,161 shares of the company's stock worth $363,000 after purchasing an additional 4,951 shares during the period. Institutional investors and hedge funds own 60.67% of the company's stock.

Lexeo Therapeutics Stock Down 8.5 %

LXEO stock opened at $2.97 on Thursday. The firm has a market capitalization of $98.69 million, a PE ratio of -0.94 and a beta of 1.27. The stock's 50 day moving average is $3.04 and its 200-day moving average is $5.31. Lexeo Therapeutics, Inc. has a twelve month low of $1.45 and a twelve month high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09. Sell-side analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on LXEO shares. HC Wainwright reissued a "buy" rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Chardan Capital lowered their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Tuesday, April 8th. Finally, Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of "Buy" and an average price target of $22.20.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.